Abstract: Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.

Abstract: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.

Abstract: Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.

Abstract: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.

Abstract: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.

Abstract: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.

Abstract: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.

Abstract: The invention is directed to human antibodies that bind CD40 (e.g., human CD40), methods of producing the antibodies and methods of use. Invention human CD40 antibodies include antibodies that can modulate one or more activities of CD40, such as increasing or decreasing cell proliferation. Invention human CD40 antibodies are therefore useful for increasing or decreasing a CD40 activity in order to alter CD40 activity in vivo.

Abstract: This invention provides pharmaceutical compositions and methods for controlling and modifying Natural Killer (NK) cell and T cell functions by manipulation of “mast cell function-associated antigen,” or “MAFA,” polypeptide-mediated cell signaling. The invention provides a pharmaceutical compositions and methods using an agent that specifically binds to an MAFA ligand on a target cell and prevents or inhibits NK- or T cell-expressed cell surface MAFA from binding to the MAFA ligand on the target cell. Preventing or inhibiting an NK- or a T cell-expressed cell surface MAFA from binding to the MAFA ligand on the target cell prevents or inhibits the cell surface MAFA from generating an inhibitory signal to the NK or the T cell.

Abstract: Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.

Abstract: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.

Abstract: Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.

Abstract: Methods for expanding T cells (e.g., V&agr;24+V&bgr;11+ human NKT cells ) in vitro by repeated culturing in the presence of an antigen (e.g., glycosphingolipid), antigen presenting cells, and a cell survival factor are provided. A population of NKT cells (V&agr;24+&zgr;&bgr;11+) can be expanded more than 1 million-fold in 5 weeks and more than 1 billion-fold in 10 weeks.

Abstract: The invention is directed to human agonistic and antagonistic antibodies that bind CD40 (e.g., human CD40), methods of producing the antibodies and methods of use. Invention human CD40 antibodies include antibodies that can stimulate or inhibit one or more activities of CD40, such as increasing or decreasing cell proliferation. Invention human CD40 antibodies are therefore useful for increasing or decreasing a CD40 activity in order to alter CD40 activity in vivo.

Abstract: This invention provides pharmaceutical compositions and methods for controlling and modifying Natural Killer (NK) cell and T cell functions by manipulation of “mast cell function-associated antigen,” or “MAFA,” polypeptide-mediated cell signaling. The invention provides a pharmaceutical compositions and methods using an agent that specifically binds to an MAFA ligand on a target cell and prevents or inhibits NK- or T cell-expressed cell surface MAFA from binding to the MAFA ligand on the target cell. Preventing or inhibiting an NK- or a T cell-expressed cell surface MAFA from binding to the MAFA ligand on the target cell prevents or inhibits the cell surface MAFA from generating an inhibitory signal to the NK or the T cell.

Abstract: The invention is directed to human antibodies that bind CD40 (e.g., human CD40), methods of producing the antibodies and methods of use. Invention human CD40 antibodies include antibodies that can modulate one or more activities of CD40, such as increasing or decreasing cell proliferation. Invention human CD40 antibodies are therefore useful for increasing or decreasing a CD40 activity in order to alter CD40 activity in vivo.

Abstract: Polypeptides, polynucleotides, fragments thereof, and monoclonal antibodies thereto are provided for antigen-specific and antigen-non-specific glycosylation inhibiting factor and a method for recombinant production of biologically active polypeptides from a structural gene encoding the polypeptide.

Abstract: Antigen non-specific human glycosylation inhibiting factor derivatives having the inmunosuppressive activity in which a mutation was introduced for replacement, deletion and/or insertion of a part of the amino acid sequence of SEQ ID NO:21, and/or which has received a chemical modification of one or more amino acid residue(s) in the amino acid sequence of SEQ ID NO:21, wherein the mutation and the chemical modification attenuate the strength of an intermolecular association in the region, which participates in trimerization, of an antigen non-specific human glycosylation inhibiting factor having the amino acid sequence of SEQ ID NO:21; DNAs containing a base sequence encoding the amino acid sequence of the antigen non-specific human glycosylation inhibiting factor derivative; recombinant vectors containing the DNAs; prokaryotic or eukaryotic cells transformed with the DNAs; methods of producing the antigen non-specific human glycosylation inhibiting factor derivatives; pharmaceutical compositions comprising t

Abstract: Polypeptides, polynucleotides, fragments thereof, and monoclonal antibodies thereto are provided for antigen-specific and antigen-non-specific glycosylation inhibiting factor and a method for recombinant production of biologically active polypeptides from a structural gene encoding the polypeptide.